[CAS NO. 162359-56-0] Fingolimod (FTY720) HCl

Name: Fingolimod (FTY720) HCl
Brand: Arctom Scientific
SKU: SLK-S5002

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [162359-56-0]

Store

Catalog

SLK-S5002

Brand

Selleck

CAS

162359-56-0

DESCRIPTION [162359-56-0]

Overview

MDL	MFCD00939512
Molecular Weight	343.9
Molecular Formula	C19H33NO2.HCl
SMILES	C(CC(CO)(CO)N)C1=CC=C(CCCCCCCC)C=C1.Cl

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.9078 mL	14.5391 mL	29.0782 mL
5 mM	0.5816 mL	2.9078 mL	5.8156 mL
10 mM	0.2908 mL	1.4539 mL	2.9078 mL
50 mM	0.0582 mL	0.2908 mL	0.5816 mL

Description

Fingolimod (FTY720, Fingolimod Hydrochloride) HCl is a antagonist with of 0.033 nM in K562, and NK cells.

Targets

S1P receptor ^[1]
(K562, NK cells )

0.033 nM

In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group.

In vivo

FTY720 is effective in Ph but not Ph ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph ALL xenografts using an early disease model. Ph human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph ALL xenografts.

References

[1] Rolin J, et al. Cancer Immunol Immunother. 2010, 59(4), 575-586.
[2] Liu Y, et al. Int J Mol Med. 2012, 30(1), 211-219.
[3] Wallington-Beddoe CT, et al. PLoS One. 2012, 7(5), e36429.
[4] Nikolova Z, et al. Transpl Immunol. 2001, 8(4), 267-277.

Synonyms

1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (1:1)

1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride

FTY 720

Fingolimod hydrochloride

2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride

Gilenya

Imusera

2-Amino-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride